Germline BRCA2 mutation is associated with greater progression-free survival in Korean women with advanced high-grade serous ovarian cancer

Ji Geun Yoo1, Hae Nam Lee2, Sung Jong Lee3, Jin Hwi Kim4, Yong Seok Lee5, Ahwon Lee6, Soo Young Hur3, Keun Ho Lee3

1 Department of Obstetrics and Gynecology, Daejeon St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2 Department of Obstetrics and Gynecology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
3 Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
4 Department of Obstetrics and Gynecology, Uijeongbu St. Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
5 Department of Obstetrics and Gynecology, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
6 Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Summary
Purpose: In this study, the effect of a germline BRCA1/2 mutation on survival outcomes in Korean patients with advanced high-grade serous ovarian cancer was investigated.

Methods: This multicenter retrospective study involved six Korean institutions that included 63 patients with International Federation of Gynecology and Obstetrics stages IIIC or IV high-grade serous ovarian cancer, diagnosed surgically between January 2010 and December 2015, and who had undergone a BRCA mutation test during their follow-up period. Median progression-free survival and 5-year overall survival were measured and compared according to BRCA1/2 mutation status using the Kaplan–Meier method.

Results: Of 63 patients, 28 (44.4%) patients with germline BRCA1/2 mutations were identified. Nineteen (30.2%) patients were identified with a germline BRCA1 mutation, and nine (14.3%) patients with a germline BRCA2 mutation. The median progression-free survival of patients with wild-type BRCA, or a BRCA1 or BRCA2 mutation was 15, 17 and 37 months, respectively. Wild-type BRCA and germline BRCA2 mutation groups showed a significant difference in progression-free survival (p = 0.009); however, a significant difference was not found between wild-type BRCA and germline BRCA1 mutation groups (p = 0.262). Five-year overall survival rates of patients with wild-type BRCA, or a BRCA1 or BRCA2 mutation were 65.9%, 67.5% and 87.5%, respectively; significant differences was not found between the three groups.

Conclusion: In Patients with advanced high grade serous ovarian cancer, germline BRCA2 mutation group showed a significantly longer median progression-free survival compared to wild-type BRCA group. Five-year overall survival rates were not significantly different among the three groups.

Date of registration: 2020-10-12

Key words: BRCA mutation; Korea; Multicenter study; Ovarian neoplasm; Survival analysis.

Introduction
The BRCA gene is a tumor suppressor gene related to hereditary ovarian cancer. Hereditary ovarian cancer accounts for over 10% of all ovarian cancers, with 90% reported to be correlated with a BRCA gene mutation [1]. The prevalence of a BRCA mutation was shown to be about 12–14% among patients with invasive ovarian cancer with racial variations [2-4]. Patients with a BRCA1 gene mutation have a 44% lifetime risk of ovarian cancer, whereas those with a BRCA2 gene mutation show about a 17% risk [5].

A BRCA1/2 mutation in patients with ovarian cancer is associated with high-grade serous ovarian carcinoma (HG-SOC) [6], a more advanced stage at diagnosis [6, 7], and an increased platinum-sensitivity [8]. A number of studies have sought to clarify the association between BRCA mutation status and survival outcome. However, most studies have included patients with various histological types and stages of ovarian cancer. Since ovarian cancer is character-
ized by heterogeneity in morphology, prognosis, pathogenesis and molecular pathology [9], survival outcomes need to be studied in more specific patient populations to better reflect the characteristics of ovarian cancer with a \textit{BRCA} mutation.

This multicenter retrospective study aimed to investigate survival outcomes according to germline \textit{BRCA} mutations among Korean patients with advanced HGSOC.

\section*{Methods}

This study was approved by The Catholic University of Korea Catholic Medical Center Institutional Review Board (XC16RIMI0004K). We retrospectively reviewed the medical records of 107 patients who underwent testing for a \textit{BRCA} gene mutation after being diagnosed with epithelial ovarian cancer between January 2010 and December 2015 in hospitals affiliated with the Catholic University of Korea, including Seoul St. Mary’s Hospital, Yeouido St. Mary’s Hospital, Bucheon St. Mary’s Hospital, Uijeongbu St. Mary’s Hospital, St. Vincent’s Hospital, and Daejeon St. Mary’s Hospital. Of these patients, 63 diagnosed with stage IIIC or IV HGSOC were included. Figure 1 shows the patient selection process. Fifty-two (82.5\%) patients underwent primary debulking surgery, and all had undergone at least six cycles of carboplatin–paclitaxel chemotherapy. The remaining 11 patients were histologically diagnosed with HGSOC by ascites cytology or biopsy, and had undergone three cycles of neoadjuvant chemotherapy with carboplatin–paclitaxel, followed by an interval debulking operation and at least three cycles of chemotherapy. We obtained EDTA-anticoagulated whole blood samples from patients during their chemotherapy cycle or a follow-up period; samples were sent to genetic laboratories to be analyzed for \textit{BRCA1/2} mutation status. St. Vincent’s Hospital proceeded with genetic testing at the Samkwang Medical Laboratories, Seoul, Korea, and Daejeon St. Mary’s Hospital undertook testing at Green Cross Genome Research Center, Yongin-si, Korea. The remaining four hospitals sent their samples to the Catholic Genetic Laboratory of Seoul St. Mary’s Hospital, Seoul, Korea. All laboratories evaluated \textit{BRCA1/2} mutation status by the Sanger sequencing method.

The medical and familial history of patients was collected at the first visit and on admission for surgery. Patients were divided into two groups: those who had a personal history of breast or ovarian cancer or one among their
Germline BRCA2 mutation is associated with greater progression-free...  

Table 1. — Clinical characteristics of patients (n = 63)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Wild-type BRCA (n = 35)</th>
<th>BRCA1 mutation (n = 19)</th>
<th>BRCA2 mutation (n = 9)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, yr</td>
<td>55.7 [39-74]</td>
<td>52.1 [38-70]</td>
<td>57.2 [45-71]</td>
<td>0.351</td>
</tr>
<tr>
<td>Mean body mass index, kg/m²</td>
<td>23.5 [18.3-33.9]</td>
<td>23.5 [19.3-28.9]</td>
<td>23.9 [20.5-30.4]</td>
<td>0.993</td>
</tr>
<tr>
<td>Menopausal</td>
<td>21 (60.0)</td>
<td>11 (57.9)</td>
<td>8 (88.9)</td>
<td>0.368</td>
</tr>
<tr>
<td>Family history positive group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>5 (14.3)</td>
<td>8 (42.1)</td>
<td>5 (55.6)</td>
<td>0.015</td>
</tr>
<tr>
<td>No</td>
<td>30 (85.7)</td>
<td>11 (57.9)</td>
<td>4 (44.4)</td>
<td></td>
</tr>
<tr>
<td>FIGO Stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIIC</td>
<td>33 (94.3)</td>
<td>17 (89.5)</td>
<td>8 (88.9)</td>
<td>0.879</td>
</tr>
<tr>
<td>IV</td>
<td>2 (5.7)</td>
<td>2 (10.5)</td>
<td>1 (11.1)</td>
<td></td>
</tr>
<tr>
<td>NAC and IDS</td>
<td>8 (22.9)</td>
<td>3 (15.8)</td>
<td>0</td>
<td>0.307</td>
</tr>
<tr>
<td>Success of R0 resection</td>
<td>29 (82.9)</td>
<td>13 (68.4)</td>
<td>7 (77.8)</td>
<td>0.609</td>
</tr>
<tr>
<td>Mean CA-125, mg/dL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>at diagnosis</td>
<td>1781.2 [115.0-9481]</td>
<td>1898.3 [107.4-5500]</td>
<td>783 [42.6-2621]</td>
<td>0.556</td>
</tr>
<tr>
<td>at the end of initial treatment</td>
<td>10.4 [1.2-38.5]</td>
<td>15.6 [3.4-96.8]</td>
<td>9.2 [2.6-27.4]</td>
<td>0.595</td>
</tr>
<tr>
<td>Recurrence</td>
<td>31 (88.6)</td>
<td>15 (78.9)</td>
<td>5 (55.6)</td>
<td>0.13</td>
</tr>
<tr>
<td>Platinum resistant recurrence</td>
<td>5 (14.3)</td>
<td>4 (21.1)</td>
<td>0</td>
<td>0.53</td>
</tr>
</tbody>
</table>


first-degree relatives were defined as part of the “family history positive group”; other patients were defined as the “sporadic group”.

During follow-up periods, the cancer antigen (CA)-125 titer and clinical findings of patients were evaluated every 3 months for the first 2 years, every 6 months for the following 3 years, and then annually. Abdominopelvic computed tomography (CT) was performed when clinical evidence of a recurrence or an elevation of the CA-125 titer was observed, otherwise CT was performed every 6 months for the first 5 years. Based on Response Evaluation Criteria In Solid Tumors (RECIST) and PET Response Criteria In Solid Tumors (PERCIST) [10, 11], the cancer recurrence date was defined as the date of detecting a recurrence of cancer. Progression free survival (PFS) was defined as the period from the start of treatment to the cancer recurrence date, and overall survival (OS) was the period from the start of treatment to death from any cause.

Statistical analysis was performed using IBM SPSS Version 20 for Windows. PFS and OS were analyzed by the Kaplan–Meier method, and significance was confirmed by log-rank test.

Results

Table 1 shows the clinical characteristics of patients. Of the 63 patients, a germline BRCA1 mutation was found in 19 (30.2%) patients, while a germline BRCA2 mutation was found in nine (14.3%) patients. None of the patients had concurrent germline BRCA1 and BRCA2 mutations. Unclassified variations of the BRCA1 gene were found in seven patients, and variations of BRCA2 were found in 14 patients.

A germline BRCA mutation was found in 13 (72.2%) of the 18 patients of the family history positive group. Eight (44.4%) patients had a germline BRCA1 mutation, and five (27.8%) patients had a germline BRCA2 mutation. In the sporadic group, 11 (24.4%) of 45 patients had a germline BRCA1 mutation, and four (8.9%) patients had a germline BRCA2 mutation. Univariate analysis for each group divided by BRCA mutation status showed a significant difference in family or personal history of breast and ovarian cancers, but significant differences in mean age, body mass index, menopausal status, successful no residual resection rate, and follow-up period were not noted.

The PFS and OS were analyzed according to BRCA gene mutation status. Kaplan-meier survival curves showing the PFS (A) and the OS (B) are presented in Figure 2. The median follow-up period was 49 months. A significantly longer median PFS was noted for the germline BRCA1/2 mutation group compared to the wild-type BRCA group (28 months [95% confidence interval (CI) 7.3–48.7] vs. 15 months [12.1–17.9], p = 0.025). The median PFS of the germline BRCA1 mutation group was 17 months (7.0–27.0), and did not show a statistically significant difference compared to that of the wild-type BRCA group (p = 0.262), while the BRCA2 mutation group showed a significantly longer median PFS (37 months [34.1–40.0], p = 0.009).

The 5-year OS was 65.9%, 67.5% and 87.5% for wild-type BRCA, and BRCA1 or BRCA2 mutation groups, respectively, without significant differences observed between groups.

Discussion

Ovarian cancer is newly diagnosed in about 240,000 people and is the cause of death in about 150,000 people
worldwide every year [12]. In Korea, about 2,400 patients are newly diagnosed with ovarian cancer yearly, and that number is gradually increasing [13]. At the time of diagnosis, about 75% of patients have advanced stage cancer [14]. About 90% of hereditary ovarian cancers, comprising over 10% of overall epithelial ovarian cancer cases, are associated with a germline BRCA gene mutation [1]. BRCA gene mutations have an autosomal dominant inheritance pattern and occur in many other cancers such as breast, stomach, colon, and pancreas. Therefore, relatives of patients with a germline BRCA mutation should consider genetic testing and counseling [15], which would enable the early diagnosis and prevention of ovarian cancer through oral contraceptives or a risk-reducing salpingo-oophorectomy [16, 17]. Furthermore, targeted therapy, such as poly ADP ribose polymerase inhibitors, have become a valuable additional treatment option [18-21].

Cancers associated with BRCA gene mutations are sensitive to chemotherapy [1, 8]. However, the suggestion that patients with BRCA mutations have better outcomes is still controversial. Previous studies attempted to determine the correlation between such mutations and overall survival. Although several studies reported better overall survival in patients with BRCA mutations [22, 23], other studies did not demonstrate the same trend [24-26].

Ovarian cancer is a heterogeneous disease, consisting of various histologic types and stages. Each shows a different chemosensitivity and oncologic outcome [9]. Previous studies were often analyzed, including various histologic types and stages. In this study, patients with high-grade serous histology and FIGO stages IIIC–IV were included to better represent the characteristics of BRCA mutant ovarian cancer. Based on these criteria, of 107 patients with nonselective epithelial ovarian cancer, 41 BRCA mutation negative patients were excluded, whereas only three BRCA mutation positive patients were excluded.

For the same reason, we analyzed the survival outcomes of patients with germline BRCA1 and BRCA2 mutations separately. Many studies have analyzed BRCA1 and BRCA2 mutations combined as one, but these genes have different functions in the homologous recombination pathway, resulting in differences in the lifetime risk of BRCA mutation–associated cancers and clinical outcomes [27]. As a result of this study, patients who have a germline BRCA2 mutation showed a marked and statistically significant median PFS compared to those without a BRCA mutation, whereas BRCA1 mutation groups showed no statistical significance. These results are consistent with a previous study in a comprehensive analysis of The Cancer Genome Atlas data [28]. In this study, we show that combining BRCA1 and BRCA2 mutations into one when undertaking survival analysis is likely to result in overestimating the survival benefit of the BRCA1 mutation.

Five-year OS rates showed no significant differences between the three groups. To date, we could obtain information about the five-year OS rates in 65.1% of all patients. Deaths related to disease progression occurred in 21 patients (33.3%), and, moreover, only one death occurred in the BRCA2 mutation group. Further data on overall survival in these patients will be updated in future studies.

To our knowledge, this is the first multicenter study conducted in Asia to analyze survival outcomes according to
BRCA mutation status. The prevalence and types of BRCA mutations in ovarian cancer differ according to ethnicity. Also, Asian ovarian cancer patients show different clinicopathologic characteristics, responses to drugs, and survival outcomes to those of westerners [29, 30]. However, only a few studies of the implication of BRCA mutations on survival outcome in patients with ovarian cancer have been conducted in Asia [8, 31]. To provide patients with more accurate survival information and to apply this to treatment, we suggest large-scale studies need to be performed.

This study has several limitations. The number of patients included in this study was small, with only nine patients with a BRCA2 mutation investigated. Larger studies are needed to accurately determine the oncological outcomes of a specific BRCA mutation status. In addition, this study evaluated germline BRCA mutation status by Sanger sequencing. However, in Korea, next-generation sequencing has been certified by the Ministry of Food and Drug Safety since 2016, while previously treated patients underwent BRCA mutation testing with Sanger sequencing. It is also known that about 50% of HGSOC is related to homologous recombination deficiency [32]. The clinical significance of genetic lesions other than germline BRCA mutations, such as somatic BRCA mutations, RAD51, ATM, BRIP1, CHEK2 mutations, and epigenetic modifications, has not been examined in this study.

In conclusion, we have demonstrated the effect of specific BRCA mutations on the survival of patients with HGSOC in this study. Compared to the wild-type BRCA group, patients with a germline BRCA2 mutation showed prolonged PFS; however, those with a BRCA1 mutation had a similar PFS to that of those with wild-type BRCA. An additional large-scale prospective study is needed to confirm these results, while the final overall survival data of this study is pending.

Acknowledgments

We would like to thank our peer reviewers and editors for their helpful comments and suggestions.

Conflict of Interest

The authors declare that they have no conflict of interest in this study.

Submitted: May 12, 2019
Accepted: October 30, 2019
Published: October 15, 2020

References


Corresponding Author:
KEUN HO LEE, M.D., Ph.D.
Department of Obstetrics and Gynecology,
Seoul St Mary’s Hospital, College of Medicine,
The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591 (Korea)
e-mail: hohoho@catholic.ac.kr